Skip to content
2000
Volume 5, Issue 2
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

It has been over 50 years since the discovery of interferon. While initially touted as “the wonder drug” for cancer therapy, the reality of interferon use as a treatment for cancer has been far different. Today, interferon is used predominantly as adjuvant therapy in renal cell carcinoma and melanoma and is being evaluated for potential new applications in other malignancies, including leukemias, lymphomas, ovarian and prostate cancer, and tumors of the central nervous system. In this review we will discuss the outcome and challenges of interferon administration in malignancies and the future of this first “cytokine” in cancer therapy.

Loading

Article metrics loading...

/content/journals/cdth/10.2174/157488510791065058
2010-05-01
2025-10-03
Loading full text...

Full text loading...

/content/journals/cdth/10.2174/157488510791065058
Loading

  • Article Type:
    Research Article
Keyword(s): anti-tumor drugs; cancer; cytokine; Interferon; malignancy; PEG-Intron; tumor
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test